Relay Medical Enters Binding LOI For Global Rights To COVID-19 Tests

Relay Medical (CSE: RELA) has entered into an arrangement to exclusively sell and distribute two separate rapid diagnostic tests for COVID-19. Announced after the bell yesterday, the arrangement is currently classified as a binding letter of intent, which was entered into with Proprietary Innovation Labs.

The arrangement will see Relay’s medical diagnostic subsidiary, HemoPalm Corp, acquire the exclusive global rights (excluding China) to sell and distribute both an antigen and an antibody test kit for COVID-19. The antigen test is notably a lateral flow rapid diagnostic test, akin to a rapid pregnancy test. Both tests are CE approved, enabling the sale and distribution within Europe and other jurisdictions.

The tests are said to be ideal for point of care testing, with results available in as little as ten minutes. The manufacturer is notably capable of producing over 25 million test kits per month, enabling significant sales opportunities should Relay develop the required sales channels.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

Further, the company is considering submitting to both Health Canada and the US Food and Drug Administration to enable domestic approval of the device as an approved COVID-19 test. Currently, the CE designation enablres the sale of the test kits in 22 countries within the European Union.

In terms of the technical data, the antigen test, which tests for active infections, has a clinical sensitivity of 95.0% and a clinical specificity of 99.6%. The antibody test, which measures immune responses in people suspected of carrying the virus, comparatively has a clinical sensitivity of 93.3% and a clinical specificity of 99.0%.

With respect to terms, the company intends to enter a definitive agreement within 45 days. Currently, it is outlined that an exclusive identifiable brand will be mutually agreed to by both parties, while profits will be shared from the sale of products. 60% of the profits from a sale will be provided to the party sourcing the purchaser, while 40% goes to the other party. Relay also issued 400,000 common shares in connection with the agreement.

Relay Medical last traded at $0.21 on the CSE.


FULL DISCLOSURE: Relay Medical Corp is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Relay Medical Corp on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Questcorp Begins 600 Metre Phase 2B Drill Program at La Union

Selkirk Copper Wraps 54,579 Metre Phase 2 Program at Minto, Hits 5.97% Copper Equivalent

Related News

FSD Pharma To Forfeit Cannabis License, Liquidate FV Pharma To Focus On Coronavirus

FSD Pharma (CSE: HUGE) (NASDAQ: HUGE) this morning announced that it is going all in...

Thursday, July 30, 2020, 08:25:40 AM

Increase in Rail Shipments Suggests Canadian Economy Beginning to Rebound

Much of Canada’s economy came to a stand-still as the coronavirus pandemic brought about lockdowns,...

Wednesday, June 3, 2020, 04:45:47 PM

Record Number of Americans Quitting Their Jobs as Fears Over Coronavirus Infections Mount

As the US Bureau of Labour Statistics released its latest Job Openings and Labour turnover...

Tuesday, August 11, 2020, 10:15:31 AM

Relay Medical Sees Fionet Joint Venture Commence Operations

After the bell last night, Relay Medical (CSE: RELA) provided a market update on the...

Thursday, August 27, 2020, 07:45:00 AM

Coronavirus Hospitalizations in Texas Continue to Soar Despite Third Phase of State Reopening

It appears that the Trump administration will soon be facing scrutiny over its push for...

Thursday, June 11, 2020, 08:27:00 PM